- AEterna Laboratories is to begin Phase I/II clinical trials with its angiogenesis inhibitor Neovastat, previously code-named AE-941, in lung, prostate and breast cancer. The trials will be conducted in Canada following the evaluation of its Investigational New Drug application by the Health Protection Branch last September. Patients refractory to standard therapies will be evaluated for the safety, tolerability and efficacy of the drug over 10 to 12 months, having received the drug for 12 weeks. In animal studies no significant toxicity was noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze